An exploratory study showed a 56% seizure reduction in the maintenance period for 10 subjects on 3-4 mg doses, increasing to 66% in the post-maintenance extension.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
